US equities
|
MU
$987.59
▼-4.02%
META
$746.64
▲+3.89%
NVDA
$225.74
▼-1.54%
SNDK
$1,481.85
▼-6.32%
SPCX
$163.79
▲+0.75%
AMD
$587.31
▼-3.42%
MSFT
$542.23
▲+1.34%
TSLA
$378.61
▼-1.07%
MU
$987.59
▼-4.02%
META
$746.64
▲+3.89%
NVDA
$225.74
▼-1.54%
SNDK
$1,481.85
▼-6.32%
SPCX
$163.79
▲+0.75%
AMD
$587.31
▼-3.42%
MSFT
$542.23
▲+1.34%
TSLA
$378.61
▼-1.07%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
United Therapeutics Corporation - Common Stock
(NQ:
UTHR
)
550.83
+1.67 (+0.30%)
Delayed Quote
Updated: 11:25 AM EDT, Oct 12, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about United Therapeutics Corporation - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
3 Reasons to Avoid UTHR and 1 Stock to Buy Instead
October 07, 2026
Since April 2026, United Therapeutics has been in a holding pattern, posting a small loss of 4.2% while floating around $541.72. The stock also fell short of...
Via
StockStory
Stocks making big moves yesterday: United Therapeutics, Moderna, Jabil, Concentrix, and FactSet
October 01, 2026
Check out the companies making headlines yesterday: United Therapeutics (NASDAQ:UTHR): Biotechnology company United Therapeutics (NASDAQ:UTHR) rose by 13.6% ...
Via
StockStory
Topics
Intellectual Property
1 Mid-Cap Stock to Research Further and 2 That Underwhelm
October 01, 2026
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. Howe...
Via
StockStory
United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia
September 30, 2026
From
United Therapeutics
Via
Business Wire
United Therapeutics (NASDAQ:UTHR): A Growth-at-a-Reasonable-Price Candidate
↗
September 24, 2026
Via
Chartmill
United Therapeutics (NASDAQ:UTHR) Screens as a High-Quality, Debt-Free Stock
↗
September 21, 2026
Via
Chartmill
United Therapeutics (NASDAQ:UTHR) Fits the Growth-at-a-Reasonable-Price Model
↗
September 03, 2026
Via
Chartmill
United Therapeutics (NASDAQ:UTHR) Stands Out as a Quality Stock with Durable Profitability and Strong Returns
↗
August 20, 2026
Via
Chartmill
Why Is United Therapeutics (UTHR) Stock Rocketing Higher Today
September 30, 2026
What Happened? Shares of biotechnology company United Therapeutics (NASDAQ:UTHR) jumped 13.6% in the afternoon session after a federal district court ruled t...
Via
StockStory
Topics
Intellectual Property
United Therapeutics Maps 14 Launches, Fibrosis Growth and Xenokidney Ambitions
↗
September 25, 2026
United Therapeutics (NASDAQ:UTHR) outlined plans to expand its pulmonary fibrosis, pulmonary hypertension and organ-manufacturing businesses at the Bernstein Healthcare Leaders and Disruptors...
Via
MarketBeat
Why United Therapeutics (UTHR) Shares Are Falling Today
September 24, 2026
What Happened? Shares of biotechnology company United Therapeutics (NASDAQ:UTHR) fell 4% in the afternoon session after Goldman Sachs initiated coverage of t...
Via
StockStory
1 Cash-Heavy Stock to Target This Week and 2 We Question
September 11, 2026
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion o...
Via
StockStory
United Therapeutics (NASDAQ:UTHR): A Peter Lynch-Style GARP Play
↗
August 13, 2026
Via
Chartmill
United Therapeutics (NASDAQ:UTHR) Tumbles as Q2 Revenue Misses Despite EPS Beat
↗
August 05, 2026
Via
Chartmill
Therapeutics Stocks Q2 Teardown: United Therapeutics (NASDAQ:UTHR) Vs The Rest
September 08, 2026
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including United Therapeutics (NASDAQ:UTHR) and its peers. Ove...
Via
StockStory
Topics
Artificial Intelligence
United Therapeutics Corporation Announces Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion Authorization
September 08, 2026
From
United Therapeutics Corporation
Via
Business Wire
3 Profitable Stocks We’re Skeptical Of
September 03, 2026
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...
Via
StockStory
United Therapeutics Corporation Announces FDA Acceptance of Supplemental New Drug Application for Nebulized Tyvaso® to Treat Idiopathic Pulmonary Fibrosis
September 02, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences
September 01, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International Congress 2026
August 28, 2026
From
United Therapeutics Corporation
Via
Business Wire
3 Cash-Producing Stocks We Keep Off Our Radar
August 26, 2026
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...
Via
StockStory
United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension
August 24, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis
August 17, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics (UTHR) Q2 2026 Earnings Call Transcript
↗
August 12, 2026
CEO Rothblatt calls H1 2026 "one of the most consequential periods" in company history.
Via
The Motley Fool
Topics
Earnings
United Therapeutics’s Q2 Earnings Call: Our Top 5 Analyst Questions
August 12, 2026
United Therapeutics reported second quarter results that modestly exceeded Wall Street’s revenue and adjusted EPS expectations, with management highlighting ...
Via
StockStory
Topics
Earnings
UTHR Q2 2026 Deep Dive: Product Pipeline Developments Offset Competitive Pressures
August 06, 2026
Biotechnology company United Therapeutics (NASDAQ:UTHR) beat Wall Street’s revenue expectations in Q2 CY2026, but sales fell by 1.9% year on year to $783.3 m...
Via
StockStory
United Therapeutics Q2 Earnings Call Highlights
↗
August 05, 2026
United Therapeutics (NASDAQ:UTHR) reported second-quarter 2026 revenue of approximately $783 million, essentially flat from the first quarter, as competitive pressure affected sales of its nebulized...
Via
MarketBeat
Topics
Earnings
United Therapeutics (NASDAQ:UTHR) Surprises With Q2 CY2026 Sales
August 05, 2026
Biotechnology company United Therapeutics (NASDAQ:UTHR) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, but sales fell by 1.9% year on yea...
Via
StockStory
Topics
Artificial Intelligence
United Therapeutics Corporation Reports Second Quarter 2026 Financial Results
August 05, 2026
From
United Therapeutics Corporation
Via
Business Wire
Earnings To Watch: United Therapeutics (UTHR) Reports Q2 Results Tomorrow
August 03, 2026
Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting results this Wednesday before the bell. Here’s what you need to know. United Therap...
Via
StockStory
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
